Pober J S, Slowik M R, De Luca L G, Ritchie A J
Molecular Cardiobiology Program, Boyer Center for Molecular Medicine, Yale University School of Medicine, New Haven, CT 06536.
J Immunol. 1993 Jun 1;150(11):5114-23.
We have investigated the role of cAMP as a signal transducer for TNF-induction of leukocyte adhesion molecule expression in cultured human umbilical vein endothelial cells (EC). Forskolin, a stimulator of adenylate cyclase, either alone or in combination with isobutyl methylxanthine (IBMX), an inhibitor of phosphodiesterase, fails to induce expression of endothelial leukocyte adhesion molecule 1 (ELAM-1 or E-selectin), of vascular cell adhesion molecule 1 (VCAM-1) or of intercellular adhesion molecule 1 (ICAM-1 or CD54). Unexpectedly, this combination of cAMP-elevating drugs inhibits TNF induction of ELAM-1 and VCAM-1 but not ICAM-1 expression. Similar results were observed with the membrane-permeant cAMP mimetics 8 bromoadenosine 3':5' cyclic monophosphate (8Br-cAMP) and N(6)2'-O-dibutyryladenosine 3':5'-cyclic monophosphate. Inhibition was greater at lower TNF concentrations (< 10 U/ml), at higher 8 Br-cAMP concentrations (> 100 microM), and at early times (2 h). Forskolin plus IBMX selectively inhibits TNF-induced increases in ELAM-1 and VCAM-1 mRNA, indicating that the action of cAMP is to block synthesis of these molecules. TNF, through stimulation of prostaglandin synthesis, produces slight elevations in the levels of endothelial cAMP. However, these increases in cAMP appear too small compared to those induced by forskolin plus IBMX to inhibit adhesion molecule expression. Indeed, complete inhibition of the TNF-mediated rise in cAMP, achieved by blocking cyclooxygenase with indomethacin, does not alter ELAM-1 expression. We conclude that cAMP is neither an intracellular mediator nor a physiological regulator of TNF-induced adhesion molecule expression in EC. However, our findings suggest that pharmacological elevations of cAMP in EC, by inhibiting TNF-induced synthesis of ELAM-1 and VCAM-1, could serve to limit inflammation.
我们研究了环磷酸腺苷(cAMP)作为肿瘤坏死因子(TNF)诱导培养的人脐静脉内皮细胞(EC)中白细胞黏附分子表达的信号转导分子的作用。腺苷酸环化酶刺激剂福斯可林,单独使用或与磷酸二酯酶抑制剂异丁基甲基黄嘌呤(IBMX)联合使用,均无法诱导内皮白细胞黏附分子1(ELAM-1或E-选择素)、血管细胞黏附分子1(VCAM-1)或细胞间黏附分子1(ICAM-1或CD54)的表达。出乎意料的是,这种升高cAMP的药物组合可抑制TNF诱导的ELAM-1和VCAM-1表达,但不影响ICAM-1的表达。使用可透过细胞膜的cAMP类似物8-溴腺苷3':5'-环一磷酸(8Br-cAMP)和N(6)2'-O-二丁酰腺苷3':5'-环一磷酸也观察到了类似结果。在较低的TNF浓度(<10 U/ml)、较高的8Br-cAMP浓度(>100 microM)以及早期(2小时)时,抑制作用更强。福斯可林加IBMX可选择性抑制TNF诱导的ELAM-1和VCAM-1 mRNA增加,表明cAMP的作用是阻断这些分子的合成。TNF通过刺激前列腺素合成,使内皮细胞cAMP水平略有升高。然而,与福斯可林加IBMX诱导的cAMP升高相比,这些升高似乎太小,不足以抑制黏附分子表达。实际上,用吲哚美辛阻断环氧化酶可完全抑制TNF介导的cAMP升高,但并不改变ELAM-1的表达。我们得出结论,cAMP既不是TNF诱导EC中黏附分子表达的细胞内介质,也不是其生理调节因子。然而,我们的研究结果表明,通过抑制TNF诱导的ELAM-1和VCAM-1合成,在EC中药物性升高cAMP可能有助于限制炎症。